Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia.

Leukemia research - 1 Nov 2022

Klink Andrew J, Gajra Ajeet, Knoth Russell L, Marshall Landon, Hou Ying, McBride Ali, Copher Ronda

Abstract excerpt

Enasidenib was approved by the Food and Drug Administration in 2017 for the treatment of patients with relapsed or refractory (RR) acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation. Given limited data in clinical practice, this study assessed real-world clinical outcomes and healthcare resource use in patients with RR AML. Physicians performed chart abstraction of patients with RR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Isocitrate Dehydrogenase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Triazines

Source

Identifiers

PMID: 36108427
DOI: 10.1016/j.leukres.2022.106946

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia.PMID 36108427Read ↗

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.Semantic proximity Read ↗

Long-term remission and survival in older adults with IDH-mutated acute myeloid leukemia treated with IDH inhibitors.Semantic proximity Read ↗

Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis.Semantic proximity Read ↗

Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials.Semantic proximity Read ↗

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.Semantic proximity Read ↗

Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis.Semantic proximity Read ↗

Enasidenib for the treatment of acute myeloid leukemia.Semantic proximity Read ↗

Real-World Outcomes of Acute Myeloid Leukemia Patients Undergoing Treatment With Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2.Semantic proximity Read ↗

Enasidenib for relapsed/refractory acute myeloid leukemia with IDH2 mutations: optimizing the patient experience.Semantic proximity Read ↗

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.Semantic proximity Read ↗

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.Semantic proximity Read ↗

Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.